|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
|
CU23923B1
(es)
*
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
US9428567B2
(en)
|
2010-12-22 |
2016-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antagonists of interleukin-2 receptor
|
|
HUE029139T2
(hu)
*
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
ES2811624T3
(es)
*
|
2011-03-11 |
2021-03-12 |
Hopitaux Paris Assist Publique |
Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
|
|
KR102220006B1
(ko)
|
2011-03-11 |
2021-02-24 |
아시스땅스 퍼블리끄-오삐또 드 빠리 |
자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ２ 의 용도
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US9481866B2
(en)
*
|
2011-12-16 |
2016-11-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing T cell populations enriched for stable regulatory T-cells
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
KR102042246B1
(ko)
|
2014-02-06 |
2019-11-28 |
에프. 호프만-라 로슈 아게 |
인터류킨-2 융합 단백질 및 이의 용도
|
|
WO2015164815A1
(en)
*
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
GB2538666A
(en)
*
|
2014-07-21 |
2016-11-23 |
Delinia Inc |
Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
WO2016025385A1
(en)
*
|
2014-08-11 |
2016-02-18 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
PH12017501856B1
(en)
*
|
2015-04-10 |
2022-08-10 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
MY188430A
(en)
*
|
2015-04-10 |
2021-12-08 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
US20170204154A1
(en)
*
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
KR102687530B1
(ko)
*
|
2016-05-04 |
2024-07-25 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
CA3019005A1
(en)
|
2016-05-18 |
2017-11-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
US11077172B2
(en)
|
2016-11-08 |
2021-08-03 |
Delinia, Inc. |
IL-2 variants for the treatment of psoriasis
|
|
CN116970059A
(zh)
|
2016-12-22 |
2023-10-31 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
IL269000B2
(en)
|
2017-03-15 |
2024-06-01 |
Cue Biopharma Inc |
Methods for modulating an immune response
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
JP2020521452A
(ja)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
標的化免疫寛容
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
AU2018300069C1
(en)
|
2017-07-11 |
2025-11-20 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
|
WO2019028419A1
(en)
*
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
|
|
EP3678677A4
(en)
*
|
2017-09-07 |
2021-06-16 |
Cue Biopharma, Inc. |
Antigen-presenting polypeptides and methods of use thereof
|
|
US20200299349A1
(en)
|
2017-11-21 |
2020-09-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
WO2019131964A1
(ja)
|
2017-12-27 |
2019-07-04 |
協和発酵キリン株式会社 |
Ｉｌ－２改変体
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2019158764A1
(en)
|
2018-02-16 |
2019-08-22 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
WO2019173832A2
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
JP7464530B2
(ja)
|
2018-03-28 |
2024-04-09 |
ブリストル－マイヤーズ スクイブ カンパニー |
インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
|
|
WO2019185705A1
(en)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma A/S |
Il-2 conjugates
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
US12459980B2
(en)
|
2018-07-25 |
2025-11-04 |
AskGene Pharma, Inc. |
IL-21 prodrugs and methods of use thereof
|
|
WO2020035482A1
(en)
|
2018-08-13 |
2020-02-20 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
ES3059360T3
(en)
|
2018-11-08 |
2026-03-19 |
Synthorx Inc |
Interleukin 10 conjugates and uses thereof
|
|
BR112021010983A2
(pt)
|
2018-12-21 |
2021-08-31 |
Jiangsu Hengrui Medicine Co., Ltd. |
Variante de interleucina-2 humana ou seu derivado
|
|
KR20260039812A
(ko)
|
2019-02-06 |
2026-03-20 |
신톡스, 인크. |
Il-2 콘쥬게이트 및 이의 사용 방법
|
|
CN113661175A
(zh)
|
2019-02-15 |
2021-11-16 |
整体分子公司 |
包含共同轻链的抗体及其用途
|
|
EP3924389A4
(en)
|
2019-02-15 |
2023-06-14 |
Integral Molecular, Inc. |
CLAUDIN-6 ANTIBODIES AND THEIR USES
|
|
AU2020252119B2
(en)
*
|
2019-03-29 |
2025-09-04 |
Centre National De La Recherche Scientifique - Cnrs |
Interleukin-2 variants with modified biological activity
|
|
WO2020236875A1
(en)
|
2019-05-20 |
2020-11-26 |
Pandion Therapeutics, Inc. |
Madcam targeted immunotolerance
|
|
AU2020287373B2
(en)
*
|
2019-06-05 |
2026-01-29 |
Asher Biotherapeutics, Inc. |
Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
|
|
KR20220020879A
(ko)
|
2019-06-12 |
2022-02-21 |
에스크진 파마, 아이엔씨. |
새로운 il-15 프로드럭 및 이를 사용하는 방법
|
|
CA3147757A1
(en)
|
2019-07-26 |
2021-02-04 |
Visterra, Inc. |
Interleukin-2 agents and uses thereof
|
|
AU2020328038B2
(en)
|
2019-08-13 |
2025-10-09 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
EP4013777A4
(en)
*
|
2019-08-15 |
2024-01-17 |
Cytimm Therapeutics, Inc. |
MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, CONJUGATES AND USES THEREOF
|
|
CN114555632A
(zh)
|
2019-08-23 |
2022-05-27 |
新索思股份有限公司 |
Il-15缀合物及其用途
|
|
MX2022002740A
(es)
|
2019-09-10 |
2022-03-25 |
Synthorx Inc |
Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
|
|
TW202128961A
(zh)
|
2019-11-20 |
2021-08-01 |
美商安維塔生物科學股份有限公司 |
細胞激素融合蛋白及其醫藥組合物及治療應用
|
|
EP4073094A1
(en)
|
2019-12-12 |
2022-10-19 |
Iltoo Pharma |
Interleukin 2 chimeric constructs
|
|
MX2022007712A
(es)
|
2019-12-17 |
2022-09-26 |
Amgen Inc |
Agonista doble de interleucina-2/receptor de tnf para uso en terapia.
|
|
BR112022012112A2
(pt)
|
2019-12-20 |
2022-09-06 |
Regeneron Pharma |
Agonistas de il2 e métodos de uso dos mesmos
|
|
US11633488B2
(en)
|
2020-01-10 |
2023-04-25 |
Bright Peak Therapeutics Ag |
Modified IL-2 polypeptides and uses thereof
|
|
WO2021142471A1
(en)
|
2020-01-11 |
2021-07-15 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
EP4090674A4
(en)
|
2020-01-14 |
2024-01-24 |
Synthekine, Inc. |
Biased il2 muteins methods and compositions
|
|
CN121319219A
(zh)
*
|
2020-01-14 |
2026-01-13 |
辛德凯因股份有限公司 |
Il2突变蛋白
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
AR121891A1
(es)
|
2020-04-22 |
2022-07-20 |
Merck Sharp & Dohme |
CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
|
|
US11897930B2
(en)
|
2020-04-28 |
2024-02-13 |
Anwita Biosciences, Inc. |
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
|
|
TW202208395A
(zh)
|
2020-05-12 |
2022-03-01 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
MX2022014082A
(es)
|
2020-06-03 |
2022-12-07 |
Ascendis Pharma Oncology Div A/S |
Secuencias de interleucina (il-2) y usos de las mismas.
|
|
MX2023000734A
(es)
*
|
2020-07-14 |
2023-02-13 |
Pfizer |
Virus vaccinia recombinante.
|
|
JP2023540701A
(ja)
*
|
2020-08-28 |
2023-09-26 |
アセンディス ファーマ オンコロジー ディヴィジョン エー／エス |
グリコシル化ｉｌ－２タンパク質及びその使用
|
|
EP4211149A4
(en)
|
2020-09-09 |
2024-10-09 |
Cue Biopharma, Inc. |
MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
|
|
EP4232071A4
(en)
|
2020-10-23 |
2024-08-28 |
Asher Biotherapeutics, Inc. |
FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
|
|
MX2023005030A
(es)
|
2020-10-29 |
2023-05-16 |
Bristol Myers Squibb Co |
Proteinas de fusion para el tratamiento de enfermedades.
|
|
CN112279906B
(zh)
*
|
2020-10-30 |
2022-09-20 |
浙江新码生物医药有限公司 |
人白细胞介素2-聚乙二醇偶联物及其制备方法与应用
|
|
CN116234912A
(zh)
|
2020-11-13 |
2023-06-06 |
江苏恒瑞医药股份有限公司 |
一种包含人白细胞介素2变体或其衍生物的药物组合物及其用途
|
|
EP4255466A1
(en)
*
|
2020-12-04 |
2023-10-11 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
CN116854802A
(zh)
*
|
2021-04-13 |
2023-10-10 |
苏州复融生物技术有限公司 |
白介素2突变体及其应用
|
|
TW202317623A
(zh)
|
2021-06-14 |
2023-05-01 |
美商再生元醫藥公司 |
基於il2之治療劑及其使用方法
|
|
WO2023281485A1
(en)
*
|
2021-07-09 |
2023-01-12 |
Bright Peak Therapeutics Ag |
Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
|
|
US20230201364A1
(en)
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Antibody conjugates and manufacture thereof
|
|
WO2023005680A1
(zh)
|
2021-07-30 |
2023-02-02 |
西安龙腾景云生物科技有限公司 |
一种人白细胞介素2变体及其用途
|
|
US20240376172A1
(en)
|
2021-10-06 |
2024-11-14 |
Iltoo Pharma |
Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
WO2024056154A1
(en)
|
2022-09-12 |
2024-03-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Interleukin-2 for use in treating autism spectrum disorder
|
|
EP4626933A1
(en)
|
2022-11-30 |
2025-10-08 |
Integral Molecular, Inc. |
Antibodies directed to claudin 6, including bispecific formats thereof
|
|
CN120529914A
(zh)
|
2023-01-09 |
2025-08-22 |
奥德赛治疗股份有限公司 |
抗tnfr2抗原结合蛋白及其用途
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2025221954A1
(en)
|
2024-04-17 |
2025-10-23 |
Visterra, Inc. |
Use of il-2 variant for treating kidney transplant rejection
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|
|
EP4707296A1
(en)
|
2024-09-05 |
2026-03-11 |
Egle Therapeutics |
Interleukin-2 variants with modified biological activity
|
|
EP4707295A1
(en)
|
2024-09-05 |
2026-03-11 |
Egle Therapeutics |
Interleukin-2 variants with modified biological activity
|